MX2021013018A - Formulacion de arnm. - Google Patents

Formulacion de arnm.

Info

Publication number
MX2021013018A
MX2021013018A MX2021013018A MX2021013018A MX2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A
Authority
MX
Mexico
Prior art keywords
mrna
present
mrna molecules
combinations
formulation
Prior art date
Application number
MX2021013018A
Other languages
English (en)
Spanish (es)
Inventor
Koker Stefaan De
Sanne Bevers
Peter Tomme
Original Assignee
Etherna Immunotherapies Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etherna Immunotherapies Nv filed Critical Etherna Immunotherapies Nv
Publication of MX2021013018A publication Critical patent/MX2021013018A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021013018A 2019-04-26 2020-04-24 Formulacion de arnm. MX2021013018A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19171323 2019-04-26
PCT/EP2020/061477 WO2020216911A1 (en) 2019-04-26 2020-04-24 Mrna formulation

Publications (1)

Publication Number Publication Date
MX2021013018A true MX2021013018A (es) 2022-03-11

Family

ID=66290283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013018A MX2021013018A (es) 2019-04-26 2020-04-24 Formulacion de arnm.

Country Status (12)

Country Link
US (1) US20220362360A1 (https=)
EP (1) EP3958893A1 (https=)
JP (1) JP7650001B2 (https=)
KR (1) KR20220023340A (https=)
CN (1) CN114096272B (https=)
AU (1) AU2020263948A1 (https=)
BR (1) BR112021021262A2 (https=)
CA (1) CA3138011A1 (https=)
IL (1) IL287560B2 (https=)
MX (1) MX2021013018A (https=)
SG (1) SG11202111720TA (https=)
WO (1) WO2020216911A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386843A1 (en) * 2019-01-04 2021-12-16 Etherna Immunotherapies Nv mRNA Vaccine
WO2020182993A1 (en) * 2019-03-13 2020-09-17 Etherna Immunotherapies Nv Mrna vaccine
CN119701015A (zh) * 2023-09-26 2025-03-28 深圳瑞吉生物科技有限公司 一种细胞因子mRNA组合药物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476419B2 (en) * 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
EP2201100B1 (en) * 2007-09-14 2016-03-16 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
HUE058792T2 (hu) 2013-11-12 2022-09-28 Univ Brussel Vrije RNS-transzkripciós vektor és felhasználása
CN120842296A (zh) * 2015-09-21 2025-10-28 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
EP3359670B2 (en) * 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes

Also Published As

Publication number Publication date
IL287560B1 (en) 2025-10-01
BR112021021262A2 (pt) 2021-12-21
EP3958893A1 (en) 2022-03-02
US20220362360A1 (en) 2022-11-17
AU2020263948A1 (en) 2021-12-23
CA3138011A1 (en) 2020-10-29
CN114096272B (zh) 2024-08-06
IL287560A (en) 2021-12-01
IL287560B2 (en) 2026-02-01
WO2020216911A1 (en) 2020-10-29
SG11202111720TA (en) 2021-11-29
KR20220023340A (ko) 2022-03-02
CN114096272A (zh) 2022-02-25
JP7650001B2 (ja) 2025-03-24
JP2022532038A (ja) 2022-07-13

Similar Documents

Publication Publication Date Title
CL2024000411A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
MX2024004936A (es) Variantes de capsides de aav y sus usos.
CR20200196A (es) Proteínas trispecìficas y mètodos de uso
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
MX2019012452A (es) Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9.
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
MX2024009660A (es) Variantes de capside de aav y usos de las mismas.
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
MX2021013018A (es) Formulacion de arnm.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
CL2017003201A1 (es) Variantes de il-37
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
BR112021014566A2 (pt) Moduladores de gpr35